El interés en corto de Eason Technology da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Eason Technology. Los datos de interés en corto se actualizan cada dos semanas.

Eason Technology (AMEX:DXF) Bolsa, Informe de interés en corto

Dunxin Financial Hldgs

Eason Technology Ltd Formerly Dunxin Financial Holdings Ltd is engaged in the business of providing loan facilities to micro, small, and medium-sized enterprises and sole proprietors in the Hubei province of the People's Republic of China. It serves family-run businesses, farmers, and individual borrowers. Some of its loan products include Consumer Loans; Commercial Loans; Collateral-Backed Loans; Enterprise Loans, and others.

ACTU

ALVO

BACK

CSBR

EVGR

GLRE

HEPA

JDZG

JYNT

LUNG

PRTA

SRRK

UNTY

VREX

YIBO

ZKIN

IMAC Holdings sube más del 108% tras anunciar Ignite Proteomics. Conoce las acciones más destacadas en la negociación previa.

Acciones de IMAC Holdings se disparan un 108%; 20 acciones en movimiento en el premercado de EE.UU.

Eason Technology Limited American Depositary Shares (each representing sixty-thousand (60,000) Ordinary Shares)

Eason Technology Ltd

Dunxin Financial Holdings Ltd ADR

Indaptus Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) ("Indaptus"), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced the sale of approximately $2.3 million in aggregate principal amount of convertible promissory notes and accompanying warrants. This transaction is being led by a healthcare-focused institutional investor in an ongoing offering in which the Company is seeking to raise up to $5 million in gross proceeds.
The notes bear interest at the rate of 6% per year and will mature on July 28, 2026. The notes will convert, together with accrued interest, into shares of common stock on the date which is the earlier of (i) the date that is 30 days from the effectiveness of a reverse split effected by the Company on Nasdaq, and (ii) the one-year anniversary from the issuance of the notes. The conversion price per share of common stock will be equal to 80% of the average Nasdaq official closing price of the common stock for the five trading days immediately preceding and including the conversion date, subject to a maximum conversion price of $0.40, as adjusted for stock splits and the like.
Warrants to purchase 200% of the conversion shares will be issued following the conversion of the notes and obtaining stockholder approval. The warrants will have an exercise price equal to the conversion price of the notes and have a term of five years from the date of issuance.
Indaptus intends to use the net proceeds from the offering for research and development activities including the funding of a Phase 1b/2 clinical trial as well as for working capital and general corporate purposes.

News

INDP

Indaptus Therapeutics Sells ~$2.3M In Aggregate Principal Amount Of Convertible Promissory Notes And Accompanying Warrants To Raise Up To $5M In Gross Proceeds

<a href="https://www.globenewswire.com/Tracker?data=wnLYJvdQVyaDsbRODSTGq4RZArab7jFNKJKyD7YSz2RgiWL-bdKatEESel6fU-xJRXxaIlQ0WL2miPUTMoVbieOta_o8QXQnvN6wtsRqEW8=">SharpLink Gaming, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) ("SharpLink" or the "Company") today announced the strategic acquisition of 176,270.69 ETH for an aggregate purchase price of $462,947,816 (inclusive of fees and expenses), at an average acquisition price of $2,626 per ETH (inclusive of fees and expenses). This acquisition positions the Company as the largest publicly-traded holder of ETH in the world, and the second largest holder behind the Ethereum Foundation.&nbsp;
In addition to the initial PIPE transaction from May 26, 2025, the Company also disclosed it raised an additional $79 million in approximate gross proceeds through its at-the-market ("ATM") facility. With a majority of the ATM proceeds used to fund further purchases of ETH, contributing to the total above, these collective purchases have generated ETH per share growth of 11.8% since June 2, 2025.
As of June 13, 2025, over 95% of SharpLink's ETH holdings are actively deployed in staking and liquid staking solutions, contributing to Ethereum's network security while generating native yield.

SBET

SharpLink Gaming Acquires 176,271 ETH For $463M At Average Acquisition Price Of $2,626 Per ETH

BRK.B Closes near high of the day
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/12221808/Screenshot-2025-06-12-at-6.12.58%E2%80%AFPM-1024x821.png" alt="" class="wp-image-14333" /></figure>
Berkshire Hathaway Inc. (BRK.B) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 10:07 AM on June 12h, a significant trading signal occurred for Berkshire Hathaway Inc., (BRK.B) as it demonstrated a Power Inflow at a price of $485.45. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Berkshire's stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Berkshire&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for BRK.B, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_June2025">https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_June2025</a>, which are responsible for parts of the data within this article.
After Market Close UPDATE:
The price at the time of the Power Inflow was $485.45. The returns on the High price ($490.43) and Close price ($490.34) after the Power Inflow are respectively 1.0% and 1.0%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. The close was near the high, but that is not always the case.
Past performance is not indicative of future results

Equities

Technicals

Opinion

Signals

Trading Ideas

Berkshire Hathaway Rises 1% After Key Trading Signal

In the latest quarter, 4 analysts provided ratings for Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>), showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Kroger, presenting an average target of $74.75, a high estimate of $82.00, and a low estimate of $71.00. This current average reflects an increase of 6.41% from the previous average price target of $70.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1749816111_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Kroger among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$73.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$71.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Ken Goldman</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$82.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>John Heinbockel</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$73.00</td>
<td>$71.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Kroger. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Kroger compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Kroger's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Kroger's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/KR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Kroger analyst ratings.</a>
<h2>Delving into Kroger's Background</h2>
Kroger is one of the largest grocery retailers in the United States with more than 2,700 stores across a portfolio of over 20 supermarket banners. The company boasts an ingrained presence in US communities, citing that it is a top-two grocer in most of its major market areas. Over one fourth of Kroger's roughly $110 billion in nonperishable and fresh food sales (about 75% of revenue) stems from its private-label portfolio, of which the company manufactures about 30% of units via its own food production plants. The company also operates fuel stations and pharmacies at 60% and 80% of its locations, respectively.
<h3>A Deep Dive into Kroger's Financials</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Negative Revenue Trend: Examining Kroger's financials over 3M reveals challenges. As of 31 January, 2025, the company experienced a decline of approximately -7.44% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Net Margin: Kroger's net margin is impressive, surpassing industry averages. With a net margin of 1.79%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Kroger's ROE excels beyond industry benchmarks, reaching 5.8%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Kroger's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.07% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Kroger's debt-to-equity ratio surpasses industry norms, standing at 3.03. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Deep Dive Into Kroger Stock: Analyst Perspectives (4 Ratings)

4 analysts have expressed a variety of opinions on Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Dolby Laboratories, revealing an average target of $100.5, a high estimate of $112.00, and a low estimate of $95.00. A decline of 2.19% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1749816098_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Dolby Laboratories. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven Frankel</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$95.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Lowers</td>
<td>Buy</td>
<td>$112.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Patrick Sholl</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Steven Frankel</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$95.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Dolby Laboratories. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Dolby Laboratories compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Dolby Laboratories's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DLB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Dolby Laboratories analyst ratings.</a>
<h2>Unveiling the Story Behind Dolby Laboratories</h2>
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company designs and manufactures audio, imaging, accessibility, and other hardware and software solutions for the cinema, with occasional applications in the television, broadcast, and live entertainment industries. The company operates in the United States and internationally.
<h3>Key Indicators: Dolby Laboratories's Financial Health</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Dolby Laboratories's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 1.38%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Dolby Laboratories's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 24.84%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Dolby Laboratories's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 3.61%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Dolby Laboratories's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.87% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Dolby Laboratories's debt-to-equity ratio is below the industry average. With a ratio of 0.02, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Dolby Laboratories Stock: Analyst Perspectives (4 Ratings)

Analysts' ratings for Bandwidth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAND#NASDAQ">BAND</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $20.5, a high estimate of $36.00, and a low estimate of $11.00. A 12.77% drop is evident in the current average compared to the previous average price target of $23.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1749816088_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Bandwidth among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>William Power</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Meta Marshall</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$11.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Bandwidth. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Bandwidth compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Bandwidth's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Bandwidth's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BAND/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Bandwidth analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Bandwidth</h2>
Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of our revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.
<h3>Bandwidth: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3M period, Bandwidth showcased positive performance, achieving a revenue growth rate of 1.88% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Communication Services sector.
Net Margin: Bandwidth's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -2.15%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -1.14%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Bandwidth's ROA stands out, surpassing industry averages. With an impressive ROA of -0.38%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Bandwidth's debt-to-equity ratio is below the industry average. With a ratio of 1.39, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BAND

The Analyst Verdict: Bandwidth In The Eyes Of 4 Experts

In the last three months, 9 analysts have published ratings on Sherwin-Williams (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $385.56, a high estimate of $420.00, and a low estimate of $350.00. Experiencing a 3.29% decline, the current average is now lower than the previous average price target of $398.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1749816074_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Sherwin-Williams among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$385.00</td>
<td>$405.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$420.00</td>
<td>$410.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$420.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$385.00</td>
<td>$405.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$350.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$375.00</td>
<td>$423.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$400.00</td>
<td>$430.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$380.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$355.00</td>
<td>$385.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Sherwin-Williams. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sherwin-Williams compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Sherwin-Williams's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Sherwin-Williams's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SHW/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sherwin-Williams analyst ratings.</a>
<h2>Get to Know Sherwin-Williams Better</h2>
Sherwin-Williams is the largest provider of architectural paint in the United States. The company has over 5,000 stores and sells premium paint at higher price points than most competitors. Sherwin-Williams also sells paint-related products in big-box stores and provides coatings for original equipment manufacturers.
<h3>Breaking Down Sherwin-Williams's Financial Performance</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Decline in Revenue: Over the 3M period, Sherwin-Williams faced challenges, resulting in a decline of approximately -1.15% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. When compared to others in the Materials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Sherwin-Williams's net margin is impressive, surpassing industry averages. With a net margin of 9.5%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Sherwin-Williams's ROE excels beyond industry benchmarks, reaching 12.32%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Sherwin-Williams's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.09%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 3.1, caution is advised due to increased financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 9 Analyst Projections For Sherwin-Williams

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $50.25, a high estimate of $80.00, and a low estimate of $31.00. This current average represents a 10.27% decrease from the previous average price target of $56.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1749816058_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Celldex Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Trung Huynh</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$38.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Richard Law</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$31.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Judah Frommer</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$50.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Edward Nash</td>
<td>Canaccord Genuity</td>
<td>Announces</td>
<td>Buy</td>
<td>$64.00</td>
<td>-</td>
</tr>
<tr>
<td>Judah Frommer</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$46.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Celldex Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Celldex Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Celldex Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CLDX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Celldex Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Celldex Therapeutics Better</h2>
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
<h3>Financial Insights: Celldex Therapeutics</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Celldex Therapeutics's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 345.51%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Celldex Therapeutics's net margin excels beyond industry benchmarks, reaching -7740.43%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Celldex Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -7.42% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Celldex Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -7.02%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Celldex Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.0.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLDX

Forecasting The Future: 8 Analyst Projections For Celldex Therapeutics

Sen.&nbsp;Elizabeth Warren&nbsp;(D-Mass.) and Sen.&nbsp;Richard Blumenthal&nbsp;(D-Conn.) raised concerns over&nbsp;Meta Platforms Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) CEO&nbsp;Mark Zuckerberg&#8216;s potential stablecoin revival plans.
What Happened: The Senators voiced their apprehensions to Zuckerberg in a letter on Wednesday, saying that reports of Meta&#8217;s pursuit of a stablecoin project raise &#8220;serious concerns.&#8221; 
The senators are worried that if large tech companies control their own private currencies, it could threaten competition, erode financial privacy, and give control of the U.S. money supply to monopolistic platforms.
Warren and Blumenthal&nbsp;argued that if Meta controlled&nbsp;its own stablecoin, it could&nbsp;exploit vast amounts of consumer data for&nbsp;&#8220;intrusive&#8221; targeted advertising, manipulate pricing, or&nbsp;sell &#8220;sensitive private information&#8221; to third parties.&nbsp;They also warned that allowing Meta&nbsp;to run a private currency&nbsp;could pose serious money laundering,&nbsp;consumer protection and national security&nbsp;threats.
The senators have&nbsp;asked Zuckerberg to provide detailed&nbsp;information about Meta&#8217;s stablecoin ambitions, including details about a potential launch, stablecoin firms consulted, and the type of partnerships being considered. They want answers by June 17.
In response to Benzinga&#8217;s inquiry, Meta cited an earlier X post by the company&#8217;s Communications Director, Andy Stone, where he said, &#8220;There is no Meta stablecoin.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">To be clear: as Mark said (and as the story notes), Diem is "dead." There is no Meta stablecoin. <a href="https://t.co/U1DN2VXM9Q">https://t.co/U1DN2VXM9Q</a>
&mdash; Andy Stone (@andymstone) <a href="https://twitter.com/andymstone/status/1920608700902916342?ref_src=twsrc%5Etfw">May 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:&nbsp;<a href="https://benzinga.com/crypto/cryptocurrency/25/06/45913575/bitcoin-ethereum-xrp-dogecoin-continue-to-struggle-as-geopolitical-tensions-rise" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, XRP, Dogecoin Continue To Struggle As Geopolitical Tensions Rise</a>
Why It Matters:&nbsp;The scrutiny follows reports that the tech giant was consulting cryptocurrency firms <a href="https://www.benzinga.com/content/45823569/is-meta-plotting-a-stablecoin-comeback-years-after-libras-flop">to introduce stablecoins as a means to manage payouts</a>, and has also hired a vice president of product with crypto experience to oversee the conversations. 
Meta initially explored the use of cryptocurrencies in its business, specifically stablecoins, in June 2019 with Libra. However, due to regulatory issues and reputational risk, the project couldn&#8217;t take off.
Price Action:&nbsp; Shares of Meta were down 0.21% in after-hours trading after closing 0.11% lower at $693.36 during Thursday&#8217;s regular trading session, according to&nbsp;<a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA.." target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.&nbsp;
The stock scored well on Momentum, Growth and Quality metrics as of this writing. Check out&nbsp;<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound" target="_blank" rel="noreferrer noopener">Benzinga Edge Stock Rankings</a>&nbsp;to see how other ‘Mag 7' stocks compare.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="553" height="347" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12223625/image-206.png" alt="" class="wp-image-948378" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12223625/image-206.png 553w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12223625/image-206-300x188.png 300w" sizes="(max-width: 553px) 100vw, 553px" /></a></figure>
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://benzinga.com/crypto/cryptocurrency/25/06/45912870/gamestops-bitcoin-strategy-draws-skepticism-amid-1-75b-debt-offering" target="_blank" rel="noreferrer noopener">GameStop&#8217;s Bitcoin Strategy Draws Skepticism Amid $1.75B Debt Offering</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo courtesy: Skorzewiak / Shutterstock.com<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" target="_blank" rel="noreferrer noopener"></a>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

Tech

Elizabeth Warren Slams Mark Zuckerberg Over Reported Stablecoin Ambitions, Citing 'National Security Threat' — Meta Says No Such Plans

In the last three months, 4 analysts have published ratings on PowerFleet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIOT#NASDAQ">AIOT</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $11.5, a high estimate of $15.00, and a low estimate of $8.00. This current average represents a 9.8% decrease from the previous average price target of $12.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1749816047_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of PowerFleet's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Jaeson Schmidt</td>
<td>Lake Street</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Alexander Sklar</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to PowerFleet. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of PowerFleet compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of PowerFleet's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of PowerFleet's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AIOT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on PowerFleet analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know PowerFleet Better</h2>
PowerFleet Inc is engaged in Internet-of-Things (IoT) solutions providing valuable business intelligence for managing high-value enterprise assets that improve operational efficiencies. It provide critical information that powers unified operations throughout organizations. It is solving the challenge of inefficient data collection, real-time visibility, and analysis that leads to transformative business operations. Its SaaS cloud-based applications take data from IoT devices and ecosystem of third-party and partner applications to present actionable information for customer.
<h3>PowerFleet: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: PowerFleet's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 207.14%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: PowerFleet's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -13.48%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): PowerFleet's ROE excels beyond industry benchmarks, reaching -3.16%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): PowerFleet's ROA stands out, surpassing industry averages. With an impressive ROA of -1.73%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 0.61, PowerFleet faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIOT

What Analysts Are Saying About PowerFleet Stock

The Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) Air Force One replacement program remains years behind schedule and billions over budget as workforce challenges and design complications continue plaguing production, a new report states. 
What Happened: The Government Accountability Office shared on Wednesday that &#8220;ongoing design issues, modification rework, and workforce challenges&#8221; are still delaying Boeing&#8217;s VC-25B presidential aircraft program, Fortune <a href="https://fortune.com/2025/06/13/boeing-air-force-one-delays-mechanic-labor-shortage/">reported </a>. The Pentagon confirmed to congressional auditors that Boeing continues struggling to hire and retain qualified mechanics due to competitive market conditions and security clearance approval bottlenecks, according to the GAO report.
Boeing signed a $3.9 billion contract in 2018 to deliver two modified 747-8 aircraft by 2024, but persistent delays have pushed completion to December 2029 or potentially &#8220;years beyond,&#8221; Boeing officials told Reuters in February. The program now faces projected costs of nearly $6.2 billion, representing at least $2 billion in cost overruns from the original contract.
Progress has stalled due to decompression system issues, environmental control design problems, and incomplete certification plans. Trump has eliminated requirements for air-to-air refueling capabilities to expedite delivery. Boeing CEO Kelly Ortberg revealed at a Barclays conference that the company is working with Elon Musk to resolve production bottlenecks, with Musk visiting Boeing&#8217;s San Antonio facility in December 2024. See Also: <a href="https://www.benzinga.com/markets/equities/25/06/45921574/lockheed-martin-rtx-general-dynamics-and-other-defense-stocks-rise-in-friday-pre-market-whats-going-on">Lockheed Martin, RTX, General Dynamics And Other Defense Stocks Rise In Friday Pre-Market: What&#8217;s Going On?</a>
Why It Matters: The extended delays have forced Trump to secure alternative transportation through a controversial $400 million Boeing 747 from Qatar&#8217;s royal family. Aviation experts warn the Qatari jet conversion could <a href="https://www.benzinga.com/25/05/45404708/trumps-boeing-jet-gift-from-qatar-could-cost-taxpayers-1-billion-and-he-still-may-not-be-able-to-use-it-this-term-say-experts">cost taxpayers up to $1 billion</a> and take years to complete, potentially extending into the 2030s before meeting presidential security standards.
Boeing&#8217;s workforce challenges reflect broader industry labor shortages despite the company announcing plans to cut 10% of its workforce last fall. The VC-25B program requires mechanics with stringent security clearances, creating additional hiring constraints. Program officials noted that &#8220;approval rates for mechanics to acquire necessary clearances remain a workforce limitation.&#8221;
The Air Force One delays add to Boeing&#8217;s operational challenges amid ongoing quality control issues across its commercial aircraft programs. The company faces FAA scrutiny over safety concerns while competing with Airbus SE (OTC:<a class="ticker" href="https://www.benzinga.com/stock/EADSF#OTC">EADSF</a>), which recently <a href="https://www.benzinga.com/markets/equities/25/06/45900237/boeing-rival-airbus-says-it-can-hit-2025-delivery-goals-amid-delays-caused-by-supply-chain-constraints">confirmed confidence in meeting its 2025 delivery targets </a>of 820 aircraft despite supply chain constraints. Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45921359/fda-expands-modernas-rsv-vaccine-use-to-at-risk-adults-aged-18-59-amid-cdc-panel-shake-up">FDA Expands Moderna&#8217;s RSV Vaccine Use To At-Risk Adults Aged 18–59 Amid CDC Panel Shake-Up</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

EADSF

Boeing's Air Force One Overhaul Delayed Again As Workforce Woes, Design Failures And Security Bottlenecks Mount, GAO Reports

D. Boral Capital analyst Jason Kolbert maintains Quince Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNCX#NASDAQ">QNCX</a>) with a Buy and maintains $4 price target.

Price Target

QNCX

D. Boral Capital Maintains Buy on Quince Therapeutics, Maintains $4 Price Target

President Donald Trump has never been one to hold back, but his latest jab at Federal Reserve Chair Jerome Powell might be aging worse than milk left out in the sun. Less than a day after <a href="https://www.benzinga.com/news/politics/25/06/45913481/trump-rips-jerome-powell-over-rates-but-supreme-court-shields-fed-from-firing">calling Powell a "numbskull"</a> for refusing to slash interest rates, the financial landscape has shifted dramatically—putting Trump's demand in an awkward position.
At a White House event on Thursday, Trump unleashed a tirade against Powell, frustrated that the Fed hadn't cut rates despite inflation remaining near a four-year low. For months, Trump has been pushing aggressively for lower rates, arguing that cutting them by two percentage points could save the government $600 billion a year in financing costs.
Vice President JD Vance also turned up the heat on Powell, calling the central bank's refusal to cut rates "monetary malpractice" in a June 12 post on X.
Read More: <a href="https://www.benzinga.com/news/politics/25/06/45898797/trump-and-jd-vance-push-fed-to-slash-interest-rates-after-mild-inflation-report-calling-current-policy-monetary-malpractice">Trump And JD Vance Push Fed To Slash Interest Rates After Mild Inflation Report, Calling Current Policy &#8216;Monetary Malpractice&#8217;</a>
But Powell, ever cautious, has refused to budge as the rate of consumer-price increases is still above the central bank&#8217;s 2% target. Trump has dismissed those concerns outright, insisting that inflation was under control and that the Fed could simply hike rates again later if needed.
Renewed Inflation Risk Suggests Powell&#8217;s Caution Is Justified
Well, the fear of higher inflation may have resurfaced faster than Trump anticipated. Within hours of his remarks, global crude prices surged as much as 14%, following Israel's large-scale airstrikes on Iran's nuclear infrastructure, reigniting fears of an inflationary shock. The sudden spike in crude prices threatens to ripple through the economy, pushing up costs for businesses and consumers alike—precisely the kind of scenario Powell had warned about when resisting Trump's aggressive push for rate cuts.
Peter Schiff, a well-known economist and financial commentator, weighed in on the situation in an X post on Thursday, highlighting the inflationary risks ahead.
"Since the May low, the oil price is up 30%," Schiff wrote. "Anyone hoping for lower inflation or Fed rate cuts based on falling oil prices needs to rethink their assumptions. Both oil prices and inflation will be higher under Trump than they were under Biden. Rate cuts will just fuel both fires."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Since the May low, the oil price is up 30%. Anyone hoping for lower inflation or Fed rate cuts based on falling oil prices needs to rethink their assumptions. Both oil prices and inflation will be higher under Trump than they were under Biden. Rate cuts will just fuel both fires.
&mdash; Peter Schiff (@PeterSchiff) <a href="https://twitter.com/PeterSchiff/status/1933337765787414948?ref_src=twsrc%5Etfw">June 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Will Trump Blink Or Double Down?
Schiff's warning underscores the dilemma now facing Trump. His argument for slashing rates hinged on the idea that inflation was under control—but with oil prices surging, the Fed's cautious approach looks increasingly justified. The geopolitical turmoil in the Middle East has thrown a wrench into Trump's economic playbook, making his "numbskull" insult to Powell seem premature at best.
In March 2022, Powell testified before the U.S. Senate Banking Committee that every $10 per barrel increase in crude oil prices raises U.S. headline inflation (CPI) by approximately 0.2 percentage points and sets back economic growth by 0.1 percentage points—a warning that feels increasingly relevant amid the latest oil price surge.
In a September 2021 study, the Federal Reserve Bank of Dallas examined the inflationary effects of rising oil prices. The research found that if crude prices climbed to $100 per barrel for three months, the annual inflation rate could increase by up to 3 percentage points in the short term.
As markets brace for further volatility, the question now is whether Trump will adjust his stance—or double down on his demand for rate cuts, even as inflation risks mount.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45798570/exclusive-should-fed-chair-powell-resign-heres-what-benzinga-readers-said">Should Fed Chair Powell Resign? Here&#8217;s What Benzinga Readers Said</a></li>
</ul>
Image created using photos from Shutterstock and Fed.

Macro Economic Events

Commodities

Politics

Economics

Trump's 'Numbskull' Insult Comes Back To Bite—In Record Time

- Patient dosing is underway in the Phase 3 CYB003 PARADIGM program in Major Depressive Disorder ("MDD") with expected combined enrollment of approximately 550 participants across three studies (APPROACH&#x2122;, EMBRACE&#x2122;, and EXTEND) -
- Partnerships with Osmind and Thermo Fisher Scientific strengthen the Company's commercialization and manufacturing capabilities -
- Positive regulatory signals from U.S. Agencies amid expanding media coverage could expedite regulatory pathways across Cybin's clinical-stage pipeline -
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cybin.com%2F&amp;esheet=54274168&amp;newsitemid=20250612856093&amp;lan=en-US&amp;anchor=Cybin+Inc.&amp;index=1&amp;md5=b33e5f4a2662caf8115f1c9d66a66bc8">Cybin Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYBN#NYSE">CYBN</a>) (Cboe Canada CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today provided a corporate update.

CYBN

Cybin Announces Patient Dosing In Phase 3 CYB003 PARADIGM Program In Major Depressive Disorder With Expected Combined Enrollment Of About 550 Participants Across Three Studies

BRTX

BioRestorative Reports Preliminary Data For FDA-Fast-Tracked BRTX-100, An Autologous Stem Cell Therapy To Treat Chronic Lumbar Disc Disease; Says Updated Data Presented At ISSCR 2025 Demonstrates >50% Improvement In Pain And Function In Significant Portion Of cLDD Subjects

The most oversold stocks in the information technology sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Clearone Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRO#NASDAQ">CLRO</a>)</h3>
<ul class="wp-block-list">
<li>On June 2, ClearOne announced it authorized a 1-for-15 reverse stock split. The company's stock fell around 27% over the past month and has a 52-week low of $4.35.</li>
<li>RSI Value: 17.9</li>
<li>CLRO Price Action: Shares of Clearone gained 1.6% to close at $5.80 on Thursday.</li>
<li>Edge Stock Ratings: 0.63 Momentum score with Value at 82.24. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/CLRO"><img loading="lazy" decoding="async" width="405" height="182" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13003541/image-207.png" alt="" class="wp-image-948444" style="width:338px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13003541/image-207.png 405w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13003541/image-207-300x135.png 300w" sizes="(max-width: 405px) 100vw, 405px" /></a></figure>
<h3 class="wp-block-heading">Cloudastructure Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSAI#NASDAQ">CSAI</a>)&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul class="wp-block-list">
<li>On May 15, Cloudastructure reported $738.00 thousand in sales for the first quarter. &#8220;Cloudastructure began 2025 with substantial momentum,&#8221; said James McCormick, Chief Executive Officer of Cloudastructure. &#8220;Revenue for the quarter more than tripled year-over-year, we turned the corner on gross profit, and we secured the largest contract in our Company&#8217;s history. The demand for real time crime deterrence has never been stronger—and we are leading the charge.&#8221; The company's stock fell around 40% over the past month and <a href="https://www.benzinga.com/quote/CSAI">has a 52-week low</a> of $1.91.</li>
<li>RSI Value: 26.6</li>
<li>CSAI Price Action: Shares of Cloudastructure closed at $2.00 on Thursday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0613">CSAI stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href=" https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0613"><img loading="lazy" decoding="async" width="915" height="820" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13004932/image-209.png" alt="" class="wp-image-948448" style="width:673px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13004932/image-209.png 915w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13004932/image-209-300x269.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13004932/image-209-768x688.png 768w" sizes="(max-width: 915px) 100vw, 915px" /></a></figure>
<h3 class="wp-block-heading">Digital Ally Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>)</h3>
<ul class="wp-block-list">
<li>On May 21, Digital Ally reported a year-over-year decrease in first-quarter sales results. &#8220;Our first quarter financial results, which included substantial non-operating gains and losses, clearly reflect the operating leverage inherent in our business model that has resulted from substantial decreases in overhead expenses, reduced headcount, and the focus on our subscription based sales model for our video solutions segment and the successful restructuring of our law enforcement products sales organization,&#8221; stated Stanton E. Ross, Chief Executive Officer of Digital Ally, Inc. The company's stock fell around 29% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/DGLY">low of $1.93</a>.</li>
<li>RSI Value: 25.9</li>
<li>DGLY Ltd Price Action: Shares of Digital Ally fell 3.2% to close at $2.84 on Thursday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0613">DGLY shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href=" https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0613"><img loading="lazy" decoding="async" width="888" height="848" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13005047/image-210.png" alt="" class="wp-image-948450" style="width:629px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13005047/image-210.png 888w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13005047/image-210-300x286.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13005047/image-210-768x733.png 768w" sizes="(max-width: 888px) 100vw, 888px" /></a></figure>
BZ Edge Rankings: Find out where other stocks stand—<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">explore the full comparison now</a>.
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45902941/top-2-defensive-stocks-that-may-keep-you-up-at-night-in-q2">Top 2 Defensive Stocks That May Keep You Up At Night In Q2</a></li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

CLRO

CSAI

DGLY

Top 3 Tech Stocks That Are Preparing To Pump This Quarter

Benchmark analyst Cody Acree reiterates Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Buy and maintains $170 price target.

Reiteration

Benchmark Reiterates Buy on Advanced Micro Devices, Maintains $170 Price Target

Rosenblatt analyst Hans Mosesmann maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Buy and maintains $200 price target.

Rosenblatt Maintains Buy on Advanced Micro Devices, Maintains $200 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy and maintains $50 price target.

HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $50 Price Target

Rosenblatt analyst Steven Frankel maintains Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) with a Buy and maintains $95 price target.

Comments

Eason Technology

Interés en corto

Eason Technology (AMEX:DXF) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL